FasL Antibodies

Target Information

Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses. TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance. Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis. Tumor necrosis factor ligand superfamily member 6, soluble form: Induces FAS-mediated activation of NF-kappa-B, initiating non-apoptotic signaling pathways. Can induce apoptosis but does not appear to be essential for this process. FasL intracellular domain: Cytoplasmic form induces gene transcription inhibition. Belongs to the tumor necrosis factor family. 2 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

ADAM10-processed FasL form; ALPS1B; APL; apoptosis (APO-1) antigen ligand 1; Apoptosis antigen ligand; APT1; APT1LG1; Apt1lg1; APTL; CD178; CD95; CD95 ligand; CD95-L; CD95L; Cd95l; Fas antigen ligand; Fas ligand; Fas ligand (TNF superfamily, member 6); Fas-L; FASL; Fasl; FasL ICD; FasL intracellular domain; FASLG; Faslg; generalized lymphoproliferative disease; gld; mutant tumor necrosis factor family member 6; Receptor-binding FasL ectodomain; sFasL; Soluble Fas ligand; SPA; SPPL2A-processed FasL form; TNFL6; Tnfs; TNFSF6; Tnfsf6; TNLG1A; Tnlg1a; tumor necrosis factor ligand 1A; tumor necrosis factor ligand 1a; Tumor necrosis factor ligand superfamily member 6; Tumor necrosis factor ligand superfamily member 6, membrane form; Tumor necrosis factor ligand superfamily member 6, soluble form